Add to Favorites
Alternative Name
Brain Tumor Fusion Panel
Test Description

The Brain Tumor NGS Fusion Panel is an RNA-based next-generation sequencing panel that detects translocations and fusions with known and novel fusion partners of these genes: ALK, BRAF, C11orf95, EGFR, EGFRvIII, EML4, ETV6, FGFR1, FGFR2, FGFR3, MET, NTRK1, NTRK2, NTRK3, ROS1, TACC3, TFG, and YAP1.

Clinical Significance
The Brain Tumor NGS Fusion Panel is intended to detect gene fusions associated with brain tumors to aid in the diagnosis, disease classification, and therapy determination. Gliomas are the most common primary brain tumors with high recurrence and mortality rates. Gene fusions are identified in 30-50% of glioblastomas (GBMs). Potentially druggable gene fusions in all GBMs include FGFR (1.2%-8.3%), EGFR (2.2%-4%), and NTRK (1.2%-1.7%). MET gene fusion (with PTPRZ1) has a 3% rate of incidence, but with an unfavorable prognosis.
Specimen Requirements
  • FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen.

CPT Code(s)*
New York Approved
Level of Service
Turnaround Time
21 Days
  1. Xu, T. et al. Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. Translational Oncology (2018) 1, 609-618.

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.